Jefferies Financial Group Inc. Makes New $2.67 Million Investment in Cogent Biosciences, Inc. $COGT

Jefferies Financial Group Inc. bought a new position in Cogent Biosciences, Inc. (NASDAQ:COGT) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 75,112 shares of the technology company’s stock, valued at approximately $2,668,000.

A number of other hedge funds have also bought and sold shares of the business. CWM LLC increased its position in shares of Cogent Biosciences by 4.9% during the 4th quarter. CWM LLC now owns 5,858 shares of the technology company’s stock valued at $208,000 after purchasing an additional 276 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Cogent Biosciences by 35.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company’s stock valued at $66,000 after purchasing an additional 488 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Cogent Biosciences by 2.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,014 shares of the technology company’s stock valued at $888,000 after purchasing an additional 527 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Cogent Biosciences by 1,164.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock valued at $25,000 after purchasing an additional 652 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Cogent Biosciences by 91.7% during the 4th quarter. GAMMA Investing LLC now owns 1,369 shares of the technology company’s stock valued at $49,000 after purchasing an additional 655 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on COGT shares. Wedbush reaffirmed an “outperform” rating and set a $55.00 price target on shares of Cogent Biosciences in a research report on Tuesday, March 17th. Jefferies Financial Group started coverage on shares of Cogent Biosciences in a research report on Monday, March 16th. They set a “buy” rating and a $55.00 price target for the company. Wall Street Zen lowered shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Friday, April 10th. Finally, HC Wainwright upped their price target on shares of Cogent Biosciences to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cogent Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $43.73.

Cogent Biosciences Trading Up 3.9%

Shares of NASDAQ:COGT opened at $33.94 on Wednesday. The stock has a 50 day moving average of $35.29 and a 200 day moving average of $36.44. The company has a market cap of $5.80 billion, a PE ratio of -15.64 and a beta of 0.37. The company has a current ratio of 15.14, a quick ratio of 15.14 and a debt-to-equity ratio of 0.41. Cogent Biosciences, Inc. has a 12-month low of $4.80 and a 12-month high of $43.73.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.53). As a group, equities research analysts expect that Cogent Biosciences, Inc. will post -2.23 EPS for the current year.

Cogent Biosciences Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.